U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210554) titled 'Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid' on Sept. 30.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Study Start Date: Nov. 11
Study Type: INTERVENTIONAL
Condition:
Bullous Pemphigoid (BP)
Intervention:
BIOLOGICAL: Stapokibart injection
subcutaneous injection
DRUG: Placebo
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chengdu Kang...